AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11929416 — intervention group
Group type: EXPERIMENTAL
Intervention: Homes with carpets and older mattresses
Number of subjects: 616
Study 11929416 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite impermeable mattress encasings
Number of subjects: 616
Study 11929416 — intervention group
Group type: EXPERIMENTAL
Intervention: Carpeted floors
Number of subjects: 616
Study 11929416 — intervention group
Group type: EXPERIMENTAL
Intervention: Older homes
Number of subjects: 616
Study 11929416 — intervention group
Group type: EXPERIMENTAL
Intervention: Woollen or synthetic blankets or synthetic quilts
Number of subjects: 616
Study 10411810 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin therapy in addition to antimicrobial agents
Number of subjects: 15
Study 10411810 — intervention group
Group type: COMPARATOR
Intervention: Antimicrobial therapy alone
Number of subjects: 15
Study 10411810 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with persistent fever but without computed tomographic evidence of septic pelvic thrombophlebitis
Number of subjects: 15
Study 10411810 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with diagnosed thrombosis
Number of subjects: 15
Study 7587731 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometric reticulocyte maturity index (RMI)
Number of subjects: 413
Study 2257800 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg
Number of subjects: 204
Study 2257800 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg plus codeine 30 mg
Number of subjects: 204
Study 6449679 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 0
Study 6449679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30246357 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine
Number of subjects: 147
Study 27906753 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon with silymarin
Number of subjects: 70
Study 27906753 — intervention group
Group type: COMPARATOR
Intervention: pegylated interferon without silymarin
Number of subjects: 70
Study 27906753 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon with or without silymarin
Number of subjects: 70
Study 25335944 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive + 4 weeks of medication (Counselor‐initiated intervention)
Number of subjects: 519
Study 25335944 — intervention group
Group type: COMPARATOR
Intervention: Reactive + 2 weeks of medication (Participant‐initiated intervention)
Number of subjects: 519
Study 24305681 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise (running at ∼70% maximum aerobic capacity)
Number of subjects: 15
Study 24305681 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie food images after high-intensity exercise
Number of subjects: 15
Study 24305681 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calorie food images after high-intensity exercise
Number of subjects: 15
Study 24305681 — intervention group
Group type: COMPARATOR
Intervention: Resting control trial (REST)
Number of subjects: 15
Study 22607192 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 1168
Study 22607192 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 1168
Study 19544817 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (AdheSE sealed, gently air-blown, light-cured)
Number of subjects: 90
Study 19544817 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (AdheSE sealed, heavily air-blown, light-cured)
Number of subjects: 90
Study 19544817 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4 (Not sealed, gently air-blown, light-cured)
Number of subjects: 90
Study 19544817 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 5 (Not sealed, heavily air-blown, light-cured)
Number of subjects: 90
Study 19544817 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (AdheSE sealed, gently air-blown, not light-cured)
Number of subjects: 90
Study 19544817 — intervention group
Group type: COMPARATOR
Intervention: Group 6 (Not sealed, gently air-blown, not light-cured)
Number of subjects: 90
Study 19544817 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (Duo-Link, AdheSE sealed, gently air-blown, light-cured)
Number of subjects: 90
Study 19544817 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (Duo-Link, AdheSE sealed, heavily air-blown, light-cured)
Number of subjects: 90
Study 19544817 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4 (Duo-Link, Not sealed, gently air-blown, light-cured)
Number of subjects: 90
Study 19544817 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 5 (Duo-Link, Not sealed, heavily air-blown, light-cured)
Number of subjects: 90
Study 19544817 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (Duo-Link, AdheSE sealed, gently air-blown, not light-cured)
Number of subjects: 90
Study 19544817 — intervention group
Group type: COMPARATOR
Intervention: Group 6 (Duo-Link, Not sealed, gently air-blown, not light-cured)
Number of subjects: 90
Study 17583395 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap (reduced-antigen-content tetanus, diphtheria, acellular pertussis)
Number of subjects: 319
Study 17583395 — intervention group
Group type: COMPARATOR
Intervention: DTaP (diphtheria-tetanus-acellular pertussis)
Number of subjects: 319
Study 15248204 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 3 DMARDs (methotrexate, sulfasalazine, hydroxychloroquine, and prednisolone)
Number of subjects: 195
Study 15248204 — intervention group
Group type: COMPARATOR
Intervention: Single DMARD (initially sulfasalazine) with or without prednisolone
Number of subjects: 195
Study 12587686 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromelain 200 mg per day
Number of subjects: 77
Study 12587686 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromelain 400 mg per day
Number of subjects: 77
Study 9535138 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer blood-pressure-lowering drugs (such as angiotensin converting enzyme inhibitors and calcium antagonists)
Number of subjects: 64000
Study 9535138 — intervention group
Group type: COMPARATOR
Intervention: Newer blood-pressure-lowering treatments
Number of subjects: 64000
Study 9535138 — intervention group
Group type: COMPARATOR
Intervention: Older classes of blood-pressure-lowering drugs
Number of subjects: 64000
Study 7640499 — intervention group
Group type: EXPERIMENTAL
Intervention: Lappaconitine 4 ml
Number of subjects: 50
Study 7640499 — intervention group
Group type: EXPERIMENTAL
Intervention: Lappaconitine 8 ml
Number of subjects: 50
Study 7640499 — intervention group
Group type: EXPERIMENTAL
Intervention: Lappaconitine 12 ml
Number of subjects: 50
Study 7640499 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NS 6 ml (Control)
Number of subjects: 50
Study 7640499 — intervention group
Group type: COMPARATOR
Intervention: Morphine 2 mg (Control)
Number of subjects: 50
Study 1325010 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced doses of lisinopril and sustained release verapamil (group III)
Number of subjects: 30
Study 1325010 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril alone (group I)
Number of subjects: 30
Study 1325010 — intervention group
Group type: COMPARATOR
Intervention: Sustained release verapamil alone (group II)
Number of subjects: 30
Study 1325010 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide with guanfacine (group IV)
Number of subjects: 30
Study 1325010 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study 6307704 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 21
Study 30311948 — intervention group
Group type: EXPERIMENTAL
Intervention: Trehalose powder with air-polishing device
Number of subjects: 44
Study 30311948 — intervention group
Group type: COMPARATOR
Intervention: Sonic device
Number of subjects: 44
Study 30257191 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin bioresorbable polymer sirolimus-eluting stent (BP SES)
Number of subjects: 1334
Study 30257191 — intervention group
Group type: COMPARATOR
Intervention: Thin durable polymer everolimus-eluting stent (DP EES)
Number of subjects: 1334
Study 26963073 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic unloader brace
Number of subjects: 36
Study 26963073 — intervention group
Group type: COMPARATOR
Intervention: Standard nonoperative treatment
Number of subjects: 36
Study 24626106 — intervention group
Group type: EXPERIMENTAL
Intervention: Store-and-Forward (SF) teledermatology
Number of subjects: 192
Study 22437952 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 46
Study 22437952 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% (placebo)
Number of subjects: 46
Study 20804290 — intervention group
Group type: EXPERIMENTAL
Intervention: Item-general practice condition
Number of subjects: 0
Study 20804290 — intervention group
Group type: EXPERIMENTAL
Intervention: Item-specific practice condition
Number of subjects: 0
Study 17592479 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg/day)
Number of subjects: 4325
Study 17592479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4325
Study 17671533 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemoradiation (surgery followed by radiation therapy at 50Gy/5 weeks, 2Gy/fraction, 5 days/week) plus chemotherapy (Leucovorin 300mg/m2 followed by 5-FU 350mg/m2)
Number of subjects: 50
Study 17671533 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiotherapy (46Gy/4.5 weeks, 2Gy/fraction, 5 days/week) followed by surgery +/- postoperative chemotherapy
Number of subjects: 50
Study 12786632 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole, metronidazole and clarithromycin (EMC)
Number of subjects: 379
Study 12786632 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole, metronidazole and clarithromycin (OMC)
Number of subjects: 379
Study 11202417 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg gossypol
Number of subjects: 77
Study 11202417 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg gossypol
Number of subjects: 77
Study 11202417 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 77
Study 9465478 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 MU natural interferon alpha for 24 weeks (group A)
Number of subjects: 99
Study 9465478 — intervention group
Group type: COMPARATOR
Intervention: 6 MU natural interferon alpha for 24 weeks (group B)
Number of subjects: 99
Study 9465478 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 99
Study 8364260 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bid
Number of subjects: 16
Study 8364260 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg bid
Number of subjects: 16
Study 8364260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2942407 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg b.i.d.)
Number of subjects: 154
Study 2942407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 2942407 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 154
Study 29648642 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal cerebral thermal therapy (maintained at 14‐16°C)
Number of subjects: 106
Study 29648642 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 106
Study 26799509 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 31
Study 26799509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 24745696 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 7.5 mg/kg, every 3 weeks for 1 year
Number of subjects: 1343
Study 24745696 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 1343
Study 24745696 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 1343
Study 22920273 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexi-T380(+) IUD
Number of subjects: 0
Study 22920273 — intervention group
Group type: COMPARATOR
Intervention: Nova-T200 IUD
Number of subjects: 0
Study 22920273 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group (other post-abortion contraception methods)
Number of subjects: 0
Study 20959424 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0
Study 20959424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17656661 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 0
Study 17656661 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intravenous and intraarterial approach to recanalization
Number of subjects: 0
Study 16320094 — intervention group
Group type: EXPERIMENTAL
Intervention: STEAM spectroscopy
Number of subjects: 22
Study 11919227 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (5-FU-based)
Number of subjects: 862
Study 11919227 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 862
Study 7523778 — intervention group
Group type: EXPERIMENTAL
Intervention: celiprolol
Number of subjects: 20
Study 7523778 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 3066856 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy alone (6,000 rads)
Number of subjects: 198
Study 3066856 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiotherapy combined with CCNU chemotherapy (100 mg/sq m every 6-8 weeks)
Number of subjects: 198
Study 30371518 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted Muscle Reinnervation (TMR)
Number of subjects: 28
Study 30371518 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (neuroma excision and burying into muscle)
Number of subjects: 28
Study 27922029 — intervention group
Group type: EXPERIMENTAL
Intervention: Eluxadoline 75 mg BID
Number of subjects: 2776
Study 27922029 — intervention group
Group type: EXPERIMENTAL
Intervention: Eluxadoline 100 mg BID
Number of subjects: 2776
Study 27922029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2776
Study 26547229 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sodium chloride with 0.15% sodium hyaluronate eye drops for 1 month
Number of subjects: 86
Study 26547229 — intervention group
Group type: COMPARATOR
Intervention: Control group without treatment for edema
Number of subjects: 86
Study 23441606 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency
Number of subjects: 904
Study 23441606 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlates of 25(OH)D concentrations
Number of subjects: 904
Study 23441606 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D concentrations
Number of subjects: 904
Study 21454456 — intervention group
Group type: EXPERIMENTAL
Intervention: Co‐trimoxazole prophylaxis continued until 2 years old
Number of subjects: 203
Study 21454456 — intervention group
Group type: COMPARATOR
Intervention: Co‐trimoxazole prophylaxis stopped immediately
Number of subjects: 203
Study 19674956 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month PAM intervention (n = 51)
Number of subjects: 102
Study 19674956 — intervention group
Group type: COMPARATOR
Intervention: Control group received a single written information brochure with brief general PA recommendations (n = 51)
Number of subjects: 102
Study 16784956 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (100-400 mg/d)
Number of subjects: 69
Study 16784956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 15382812 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm/hand splint
Number of subjects: 43
Study 15382812 — intervention group
Group type: COMPARATOR
Intervention: Elbow band
Number of subjects: 43
Study 11751732 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg sublingual nitroglycerin (NTG)
Number of subjects: 36
Study 11751732 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 36
Study 9420016 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination 5‐FU plus leucovorin (LV)
Number of subjects: 12
Study 9420016 — intervention group
Group type: COMPARATOR
Intervention: Monthly schedule of 5‐FU/LV (200 mg/m2)
Number of subjects: 12
Study 9420016 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly schedule of 5‐FU/LV (high-dose LV)
Number of subjects: 12
Study 9420016 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic commercial formulation of LV
Number of subjects: 12
Study 9420016 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential methotrexate/5‐FU
Number of subjects: 12
Study 9420016 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion schedules of 5‐FU
Number of subjects: 12
Study 8305958 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) at a dose of 400 mg/kg
Number of subjects: 33
Study 8305958 — intervention group
Group type: COMPARATOR
Intervention: Placebo (albumin)
Number of subjects: 33
Study 2849460 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 0
Study 2849460 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 31894236 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg testosterone enanthate/week
Number of subjects: 50
Study 31894236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31056148 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher vegetable dietary pattern scores
Number of subjects: 987
Study 27776926 — intervention group
Group type: EXPERIMENTAL
Intervention: With load (4-kg) during 90° shoulder abduction maximal humeral external rotation (90°er)
Number of subjects: 25
Study 27776926 — intervention group
Group type: COMPARATOR
Intervention: Without load (NL) during 90° shoulder abduction neutral (90°neutral)
Number of subjects: 25
Study 25444751 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAMTS13
Number of subjects: 17
Study 25444751 — intervention group
Group type: EXPERIMENTAL
Intervention: HSP27
Number of subjects: 17
Study 25444751 — intervention group
Group type: EXPERIMENTAL
Intervention: sP‐Selectin
Number of subjects: 17
Study 25444751 — intervention group
Group type: COMPARATOR
Intervention: Systolic Blood Pressure (SBP)
Number of subjects: 17
Study 25444751 — intervention group
Group type: COMPARATOR
Intervention: Base Deficit (BD)
Number of subjects: 17
Study 25444751 — intervention group
Group type: COMPARATOR
Intervention: Heart Rate (HR)
Number of subjects: 17
Study 25444751 — intervention group
Group type: COMPARATOR
Intervention: Shock Index (SI)
Number of subjects: 17
Study 25444751 — intervention group
Group type: COMPARATOR
Intervention: Tissue Oxygen Saturation (StO2)
Number of subjects: 17
Study 22711752 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg b.i.d.
Number of subjects: 42
Study 22711752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 22863658 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hep B-PRP-T vaccine
Number of subjects: 1189
Study 22863658 — intervention group
Group type: COMPARATOR
Intervention: Licensed hexavalent control vaccine (Infanrix™ hexa)
Number of subjects: 1189
Study 22863658 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hep B-PRP-T booster
Number of subjects: 1189
Study 19423470 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential intravenous (i.v.) to oral (p.o.) moxifloxacin 400 mg once daily
Number of subjects: 595
Study 19423470 — intervention group
Group type: COMPARATOR
Intervention: i.v. ceftriaxone 2 g once daily plus metronidazole 500 mg three times daily, followed by p.o. amoxicillin/clavulanate 625 mg three times daily
Number of subjects: 595
Study 19423470 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (moxifloxacin and ceftriaxone/metronidazole)
Number of subjects: 595
Study 18270944 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal meperidine (15 mg) plus 75 mg of hyperbaric lidocaine 5%
Number of subjects: 80
Study 18270944 — intervention group
Group type: COMPARATOR
Intervention: Normal saline plus 75 mg of hyperbaric lidocaine 5%
Number of subjects: 80
Study 15105167 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (0.9 pmol x kg(‐1) x min(‐1))
Number of subjects: 0
Study 15105167 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-33 (0.2 pmol x kg(‐1) x min(‐1))
Number of subjects: 0
Study 15105167 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 plus CCK-33
Number of subjects: 0
Study 11552922 — intervention group
Group type: EXPERIMENTAL
Intervention: rabeprazole 10 mg plus amoxicillin 750 mg and clarithromycin 200 mg
Number of subjects: 102
Study 11552922 — intervention group
Group type: EXPERIMENTAL
Intervention: rabeprazole 20 mg plus amoxicillin 750 mg and clarithromycin 200 mg
Number of subjects: 102
Study 11552922 — intervention group
Group type: EXPERIMENTAL
Intervention: rabeprazole 40 mg plus amoxicillin 750 mg and clarithromycin 200 mg
Number of subjects: 102
Study 11552922 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 extensive metabolizers
Number of subjects: 102
Study 11552922 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 poor metabolizers
Number of subjects: 102
Study 11552922 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events in extensive metabolizers
Number of subjects: 102
Study 11552922 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events in poor metabolizers
Number of subjects: 102
Study 9625181 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home comprehensive geriatric assessment and preventive care
Number of subjects: 202
Study 7946364 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 600 micrograms/kg intubation dose
Number of subjects: 36
Study 7946364 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance doses of rocuronium
Number of subjects: 36
Study 7946364 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversal of rocuronium-induced neuromuscular block
Number of subjects: 36
Study 7946364 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic analysis of rocuronium
Number of subjects: 36
Study 2884682 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 10
Study 2884682 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam
Number of subjects: 10
Study 2884682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10